DC Vaccine in Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

February 12, 2024

Study Completion Date

February 12, 2024

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

mDC3/8-KRAS Vaccine

Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma

Trial Locations (1)

University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

University of Pennsylvania

OTHER

NCT03592888 - DC Vaccine in Pancreatic Cancer | Biotech Hunter | Biotech Hunter